Bristol-Myers Squibb has expanded its 2012 collaboration with Tsinghua University to add identification, validation, discovery and development of new autoimmune disease and cancer targets. Under the expanded deal, BMS gets the option to license exclusive rights to compounds discovered in the agreement.
BMS, Tsinghua expand deal on autoimmune diseases, cancer
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.